Molecular Formula | C29H40N8O3S |
Molar Mass | 580.74 |
Density | 1.276 |
Boling Point | 794.3±70.0 °C(Predicted) |
pKa | 8.14±0.42(Predicted) |
Storage Condition | -20℃ |
In vitro study | ASP3026 showed more selective inhibition of ALK activity in tyrosine kinase than pf02341066. ASP3026 inhibits the growth of the Endogenously expressed NCI-H2228 mutant 3 in the human non-small cell lung cancer tumor cell line EML4-ALK with an IC 50 of 64.8 nM. ASP3026 showed stronger selective inhibition of ALK activity in tyrosine kinase than pf02341066. ASP3026 inhibits the growth of the Endogenously expressed NCI-H2228 mutant 3 in the human non-small cell lung cancer tumor cell line EML4-ALK with an IC 50 of 64.8 nM. |
In vivo study | Given to subcutaneous NCI-H2228 tumor xenograft mice for oral administration of ASP3026 twice daily for 14 days, induced a dose-dependent antitumor effect, with onset of action at 1 mg/kg, 30 and 100 mg/kg have a strong inhibitory effect. administration of ASP3026 orally twice daily for 14 days to subcutaneous NCI-H2228 tumor xenograft mice induced a dose-dependent antitumor effect, with onset of action at 1 mg/kg, 30 and 100 mg/kg have a strong inhibitory effect. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.722 ml | 8.61 ml | 17.219 ml |
5 mM | 0.344 ml | 1.722 ml | 3.444 ml |
10 mM | 0.172 ml | 0.861 ml | 1.722 ml |
5 mM | 0.034 ml | 0.172 ml | 0.344 ml |